Monoclonal antibodyFDA-approvedFirst-line
Avastin
Generic name: bevacizumab
How it works
Blocks the formation of new blood vessels that feed the tumor, starving it of oxygen and nutrients.
Cancer types
Colorectal Cancer— All patients
Lung Cancer— All patients
Efficacy
In clinical trials, Avastin improved overall survival and progression-free survival in patients with metastatic colorectal cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Older Colorectal Cancer Patients' Response to Trifluridine/Tipiracil with or without Bevacizumab | Colorectal Cancer | observational | Median OS was longer in the combination therapy group (18.3 vs. 8.3 months). | Source → |
| Testing IBI363 Combined with Bevacizumab for Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Ovarian Cancer Trial Examines Bevacizumab's Effectiveness | Ovarian Cancer | phase-2 | — | Source → |
| New Gene Signatures May Help Predict Bevacizumab Response in Ovarian Cancer | Ovarian Cancer | lab-study | Over-expression of the signature was associated with improved overall survival in patients who received bevacizumab (HR = 0.41, 95% CI: (0.23-0.74), adj.p-value = 0.008). | Source → |
| Testing ABBV-400 for Advanced Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Melanoma Trial Examines Combination Therapy | Melanoma | phase-2 | — | Source → |
| Removing Bevacizumab from the Body Before Surgery | Colorectal Cancer | observational | — | Source → |
| Bevacizumab and Chemotherapy May Improve Survival for Elderly Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 47 months and the median progression-free survival was 24 months in the bevacizumab group. | Source → |
| Testing Lurbinectedin with Paclitaxel and Bevacizumab in Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Olaparib plus bevacizumab may be cost-effective for ovarian cancer patients in China | Ovarian Cancer | phase-3 | — | Source → |
| Testing Pembrolizumab and Paclitaxel for Recurring Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Combining pralsetinib and bevacizumab may improve lung cancer treatment | Lung Cancer | lab-study | — | Source → |
| Blocking VEGF-A Improves Survival in Lung Cancer Patients with Liver Metastases | Lung Cancer | phase-3 | The addition of bevacizumab to CT+IT significantly improved progression-free survival (PFS; HR: 0.49) and OS (HR: 0.52) in LM+ patients. | Source → |
| Testing New Treatments for Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Testing Combination Therapy for Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Combination Therapy Trial for Metastatic Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Durvalumab and Chemotherapy Combination for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Testing Treatments for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Inflammation May Affect How Well Bevacizumab Works in Lung Cancer | Lung Cancer | observational | Bevacizumab significantly improved overall survival in patients with high CRP levels (hazard ratio 0.63; 95% confidence interval, 0.40-0.99; p = 0.04). | Source → |
| Evaluating Mirvetuximab Soravtansine and Bevacizumab in Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Testing Trastuzumab Deruxtecan and Bevacizumab for Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Japanese Colorectal Cancer Patients Participating in Observational Study of Bevacizumab Biosimilar | Colorectal Cancer | preclinical | — | Source → |
| Testing Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Bevacizumab Linked to Severe Blood-Related Side Effects in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Combination Therapy for Ovarian Cancer: A Phase II Clinical Trial | Ovarian Cancer | phase-2 | — | Source → |
| Bevacizumab May Help Prevent Lung Disease in Lung Cancer Patients | Lung Cancer | observational | Bevacizumab use was associated with lower risks of ILD [SHR, 0.75; 95% confidence interval (CI), 0.67-0.84], 180-day mortality (HR, 0.61; 95% CI, 0.57-0.66), and mortality within 30 days after ILD (HR, 0.71; 95% CI, 0.57-0.88). | Source → |
| Combining Chemotherapy and Surgery for Colorectal Cancer | Colorectal Cancer | phase-2 | Neoadjuvant therapy with mFOLFOXIRI plus bevacizumab can reduce peritoneal tumor burden without increasing surgical risk, and may improve progression-free survival. | Source → |
| Testing a New Combination Therapy for Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating Treatments for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Evaluating a New Treatment for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The objective response rate was 18.3%, and the disease control rate was 83.3%. | Source → |
| Ovarian Cancer Treatment Trial Investigates New Combination Therapy | Ovarian Cancer | phase-2 | — | Source → |
| Combining furmonertinib and bevacizumab improves survival in lung cancer patients | Lung Cancer | phase-2 | Combination therapy with bevacizumab plus high-dose furmonertinib significantly improved the LM response compared to that of furmonertinib monotherapy (median iPFS: 6.77 vs 4.04 months, respectively, 95% CI: 0.41-0.98, p = 0.038; median OS: 15.31 vs 7.10 months, respectively, 95% CI: 0.29-0.82, p = 0.002). | Source → |
| Lung Cancer Brain Metastases Treatment Trial | Lung Cancer | phase-3 | — | Source → |
| Osimertinib and Bevacizumab for EGFR Positive Non-Small Cell Lung Cancer with Brain Metastases | Lung Cancer | phase-2 | — | Source → |
| Testing Oregovomab with Chemo and Bevacizumab in Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing Ivonescimab and Bevacizumab in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Testing Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating Pumitamig and Bevacizumab in Colorectal Cancer Treatment | Colorectal Cancer | phase-2 | — | Source → |
| Testing Olaparib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| New Treatment Combination Tested for Lung Cancer Patients with Brain Metastases | Lung Cancer | phase-1 | — | Source → |
| Evaluating Treatment Options for Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Bevacizumab Added to Chemotherapy May Improve Lung Cancer Progression-Free Survival | Lung Cancer | phase-3 | The hazard ratio for progression-free survival was 0.69 (95% CI 0.52-0.92) in favor of the bevacizumab group. | Source → |
| Testing IACS-6274 with or without Bevacizumab and Paclitaxel for Advanced Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Pegylated Liposomal Doxorubicin and Immunotherapy in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Bevacizumab in Rare Solid Tumors | Lung Cancer | phase-2 | — | Source → |
| Ovarian Cancer Treatment Trial: Pembrolizumab and Paclitaxel Combination | Ovarian Cancer | phase-3 | — | Source → |
| Cannabidiol and Bevacizumab Combo Tested | Lung Cancer | lab-study | The apoptotic rate was 15.23% ± 0.42 following cannabidiol treatment and 21.97% ± 0.50 following bevacizumab treatment, and combined treatment significantly increased apoptosis to 50.47% ± 0.67 (< 0.001). | Source → |
| Combination Therapy Extends Survival in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | The median overall survival was 8.9 months for FTD-TPI+bev and 5.8 months for FTD-TPI (P<0.001). | Source → |
| US Doctors' Choices for Treating Advanced Colorectal Cancer | Colorectal Cancer | observational | — | Source → |
| Researchers Identify New Pathway Behind Bevacizumab Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Bevacizumab Not Cost-Effective for Some Colorectal Cancer Patients | Colorectal Cancer | phase-3 | — | Source → |
| Long-Term Survival in Advanced Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Niraparib May Offer Better Progression-Free Survival for Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 13.77 months in the bevacizumab group. | Source → |
| Combining treatments for a rare type of colon cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 17.2 months compared to 10.7 months (HR 0.60) in the MSS subgroup. | Source → |
| Bevacizumab's Effectiveness in Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| New Lung Cancer Treatment Combination Shows Promise | Lung Cancer | phase-3 | Serplulimab plus chemotherapy significantly prolonged OS and maintained PFS benefit compared to chemotherapy; however, the addition of bevacizumab biosimilar HLX04 did not yield further improvement for the first-line treatment of nsq-NSCLC without or genetic alterations. | Source → |
| Macrophages Linked to Treatment Resistance in Colorectal Cancer | Colorectal Cancer | lab-study | A high density of intratumoral CD68CD163 M2-like TAMs was significantly associated with shorter overall survival (OS) (p < 0.05) and showed a trend toward shorter progression-free survival (PFS) (p = 0.06). | Source → |
| Cost-Effectiveness of Lung Cancer Treatment Questioned | Lung Cancer | phase-3 | Nivolumab plus bevacizumab and chemotherapy yielded an additional 0.90 QALYs with the marginal cost of $231,948.33. | Source → |
| ERBB2-amplified colorectal cancer patients have poorer outcomes with current treatments | Colorectal Cancer | observational | Median progression-free survival was 7.6 months for ERBB2 amp+ patients compared to 8.7 months for ERBB2 amp- patients. | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Bevacizumab May Reduce Lung Inflammation in Cancer Patients | Lung Cancer | observational | — | Source → |
| Ovarian Cancer Patients on PARP Inhibitors May Face Blood Clot Risk | Ovarian Cancer | observational | Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095-0.724; p = 0.010). | Source → |
| Comparing Bevacizumab Doses in Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| USP7's role in ovarian cancer resistance to bevacizumab | Ovarian Cancer | lab-study | — | Source → |
| Olaparib plus bevacizumab in older ovarian cancer patients: manageable safety and quality of life | Ovarian Cancer | phase-3 | Two years after randomization, mean Global Health Status and cognitive functioning seemed better with olaparib than bevacizumab alone (adjusted mean difference: +4.47 points and +4.82 points, respectively). | Source → |
| Bevacizumab's Effect on Ovarian Cancer Treatment | Ovarian Cancer | observational | Among patients with high-risk prognostic factors, median real-world time to next treatment was significantly longer with 1L chemotherapy plus bevacizumab (13.6 [12.7-15.9] months) than chemotherapy alone (11.7 [10.6-12.6] months; p = .032). | Source → |
| Bevacizumab's Role in Treating Advanced Ovarian Cancer | Ovarian Cancer | review | — | Source → |
| Bevacizumab May Help Ovarian Cancer Patients Who Can't Have Surgery | Ovarian Cancer | observational | Median overall survival for unresectable patients showed no significant difference, but bevacizumab significantly improved OS in the CPB group (not reached vs.18 months, p = 0.015) | Source → |
| Combination Therapy Shows Promise for Untreated Melanoma Brain Metastases | Melanoma | phase-2 | The brain metastasis response rate was 54.1% (95% CI, 36.9 to 70.5). | Source → |
| Bevacizumab and Chemotherapy Combination Shows Promise in Ovarian Cancer Treatment | Ovarian Cancer | phase-2 | The research group showed a disease remission rate of 80.00% and a treatment effectiveness rate of 95.56%. | Source → |
| Biosimilar CT-P16 Shows Equivalent Efficacy in Lung Cancer Treatment | Lung Cancer | phase-3 | Objective response rates were 45.6% and 46.1% for CT-P16 and EU-bevacizumab, respectively. | Source → |
| Real-world outcomes of ovarian cancer patients on niraparib-bevacizumab maintenance therapy | Ovarian Cancer | phase-2 | Median time to treatment discontinuation was 11.8 months (95% CI 8.7 to 13.5), and median time to next treatment was 14.1 months (95% CI 11.3 to 16.6). | Source → |
| Rare Side Effect of Cancer Treatment: A Case Report | Colorectal Cancer | observational | — | Source → |
| Chemotherapy Combination Shows Promise for Advanced Rectal Cancer | Colorectal Cancer | phase-2 | The response rate to preoperative chemotherapy was 92.3% | Source → |
| Bevacizumab May Cause Delayed Anastomotic Leaks in Colorectal Cancer Patients | Colorectal Cancer | observational | — | Source → |
| Bevacizumab May Help in Advanced Ovarian Cancer | Ovarian Cancer | observational | — | Source → |
| Unclassified TP53 mutations linked to better survival in ovarian cancer patients | Ovarian Cancer | preclinical | Patients with TP53 missense mutations of unknown function had a hazard ratio of 0.43 for overall survival. | Source → |
| Ovarian Cancer Study in Finland Examines Treatment Outcomes | Ovarian Cancer | observational | Bevacizumab treatment at any line at stages III/IV improved OS in the short-term only. | Source → |
| Combining Bevacizumab with Chemotherapy May Help Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 11 months in the group that received bevacizumab and chemotherapy, and 9 months in the group that received chemotherapy alone. | Source → |
| Chemotherapy for Gynecologic Cancers Can Be Very Expensive | Ovarian Cancer | observational | — | Source → |
| Bevacizumab Treatment Extends Survival in Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 20 months, and overall survival was 58 months. | Source → |
| Bevacizumab's Place in Lung Cancer Treatment | Lung Cancer | review | — | Source → |
| New Treatment Combination Shows Promise for Ovarian Clear Cell Cancer | Ovarian Cancer | phase-2 | — | Source → |
| New Lab Study Examines Uveal Melanoma Treatments | Melanoma | lab-study | The IC concentration of bevacizumab was 6.945 mg/mL. | Source → |
| Combining IOX1 and Bevacizumab May Help Treat Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Trifluridine/Tipiracil Combinations Show Promise in Advanced Colorectal Cancer | Colorectal Cancer | review | Median overall survival ranged 8.6-14.4 months and median progression-free survival 3.7-6.8 months with FTD/TPI plus bevacizumab in refractory mCRC. | Source → |
| New Treatment Combination Shows Modest Activity in Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | The objective response rate was 17.1% (80% CI, 9.8 to 27.0), including one complete response (2.4%). | Source → |
| New Insights into Ovarian Clear Cell Carcinoma Treatment | Leukemia | observational | Patients with advanced/relapsed OCCC who received platinum-based chemotherapy plus bevacizumab followed by maintenance bevacizumab had a median first-line progression-free survival of 12.2 months. | Source → |
| Osteonecrosis of the jaw linked to bevacizumab after radiation | Colorectal Cancer | observational | — | Source → |
| Cost-effectiveness of bevacizumab biosimilar for ovarian cancer | Ovarian Cancer | phase-3 | — | Source → |
| Combining gene silencing and bevacizumab may help treat colorectal cancer | Colorectal Cancer | animal-study | — | Source → |
| New Treatment Option for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | Median progression-free survival was 8.4 months, and median overall survival was 17.6 months in the SALIRI group. | Source → |
| Combining Drugs May Help Some Lung Cancer Patients | Lung Cancer | preclinical | — | Source → |
| Ovarian Cancer Patients Treated with Bevacizumab May Not Experience Deterioration in Quality of Life | Ovarian Cancer | meta-analysis | — | Source → |
| Chemotherapy and Bevacizumab Combination for Ovarian Cancer | Ovarian Cancer | observational | The median overall survivals were 37.9 months in the CGB arm, 41.0 months in the CPB arm, and 41.3 months in the CLdB arm. | Source → |
| Lactate in Tumors May Affect Bevacizumab Treatment in Colorectal Cancer | Colorectal Cancer | lab-study | Combining inhibition of histone lactylation and macroautophagy/autophagy with bevacizumab treatment demonstrated remarkable treatment efficacy. | Source → |
| Olaparib plus Bevacizumab May Be Cost-Effective for Advanced Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| New Options for Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | The risk of death was significantly decreased with carboplatin + pegylated liposomal doxorubicin + bevacizumab compared to platinum-based doublet CT (hazard ratio [HR] = 0.59, 95%CI 0.35, 1). | Source → |
| Long-term Bevacizumab Treatment and Adverse Events in Colorectal Cancer | Colorectal Cancer | observational | — | Source → |
| Bevacizumab Treatment in Ovarian Cancer: Chinese Study Results | Ovarian Cancer | observational | The patients in the first-line chemotherapy group had a median progression-free survival of 15 months, and the 12-month progression-free survival was 61.7%. | Source → |
| Bevacizumab May Help Advanced Low Grade Serous Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 47.86 months for patients receiving Bevacizumab with chemotherapy in the first line setting, and 37.1 months in the recurrent setting. | Source → |
| Combination Therapy for Recurrent Ovarian and Peritoneal Cancer | Ovarian Cancer | phase-2 | The response rate in platinum-sensitive recurrence was 33.3%, and 7.1% in platinum-resistant recurrence. | Source → |
| Smoking's Impact on Breast Cancer Treatment with Bevacizumab | Breast Cancer | observational | Time to treatment failure was significantly longer in the high packs-years group than the low packs-years group (p=0.010, log-rank). | Source → |
| Choosing the Right Maintenance Therapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| BRAF Mutant Melanoma Cells May Depend on VEGF for Growth | Melanoma | lab-study | Bevacizumab induced significant tumor growth delay, reduced vascularity, and increased necrosis in BRAF xenografts. | Source → |
| Combining Bevacizumab and Chemotherapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | Partial response was achieved in 2 patients (20%) and a R0 liver metastases resection in one patient. | Source → |
| TAS-102 Monotherapy and Combination Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | observational | The objective response rate was 1.4%, and the disease control rate was 68.6%. | Source → |
| Olaparib and Bevacizumab Benefit High-Grade Ovarian Cancer Patients with BRCA Mutations | Ovarian Cancer | phase-3 | The 24-month PFS rate was estimated to be 89% and 15% for patients with BRCA1m located in the DBD, with a hazard ratio of 0.08 (olaparib + bevacizumab versus placebo + bevacizumab). | Source → |
| Bevacizumab May Help Ovarian Cancer Patients with Low VEGF-A165b Expression | Ovarian Cancer | phase-3 | The addition of bevacizumab to standard platinum-based chemotherapy significantly improved progression-free survival (HR: 0.727) and overall survival (HR: 0.662) in patients with low VEGF-A165b expression. | Source → |
| New Study Identifies Patients Most Likely to Benefit from Bevacizumab in Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.87 in patients with an unfavorable KELIM score. | Source → |
| Bevacizumab's Effectiveness in Colorectal Cancer | Colorectal Cancer | lab-study | CSPG4 positive group had better objective response rate, as well as longer progression-free and overall survival than CSPG4 negative ones. | Source → |
| Bevacizumab and Gastrointestinal Perforation in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Long-term Bevacizumab Treatment for Ovarian Cancer May Cause Adverse Events | Ovarian Cancer | observational | — | Source → |
| New DNA Signature May Help Predict Bevacizumab Effectiveness in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Ovarian Cancer Study Finds No Benefit in Adding Pazopanib to Paclitaxel | Ovarian Cancer | phase-2 | There was no difference between treatment arms in 4-month progression-free survival rate (61% with the combination versus 68% with paclitaxel alone). | Source → |
| Chromosome Loss Linked to Bevacizumab Benefit in Colorectal Cancer | Colorectal Cancer | phase-3 | Significant progression-free survival benefit of bevacizumab was observed in patients with chromosome 18q11.2-q12.1 loss (P = .009), and not in patients without 18q loss (P = .67). | Source → |
| New Hope for Ovarian Cancer Patients with Brain Metastasis | Ovarian Cancer | observational | Median survival in patients treated after bevacizumab approval was 33.5 months. | Source → |
| Bevacizumab's Role in Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| PARP-inhibitors may be more effective than bevacizumab for ovarian cancer | Ovarian Cancer | meta-analysis | PARPi improved PFS significantly more than bevacizumab in women with a BRCA1/2 mutation (HR 0.47; 95% CI 0.36-0.60) and with homologous-recombination deficiency (HR 0.66; 95% CI 0.50-0.87). | Source → |
| New Cancer Treatment QL1101 Shows Similar Efficacy to Bevacizumab | Lung Cancer | phase-3 | The two-year updated data showed similar objective response rates (QL1101 53.1%, bevacizumab 54.3%), progression-free survival (235 d 254 d), and overall survival (577 d 641 d) results between the QL1101 group and the bevacizumab group. | Source → |
| Combining Bevacizumab and Capecitabine May Help Some Colorectal Cancer Patients | Colorectal Cancer | observational | The median progression-free survival was 9.0 months in the observation group and 7.2 months in the control group. | Source → |
| Chemotherapy with Bevacizumab Does Not Affect Quality of Life for Breast Cancer Patients | Breast Cancer | phase-3 | — | Source → |
| Researchers Investigate Chemotherapy for Rare Lung Cancer | Leukemia | phase-2 | The overall response rate was 25.0% and disease control rate was 56.3%. | Source → |
| Combination Therapy for Esophageal Cancer Shows Promise | Leukemia | phase-3 | The total treatment efficiency in the study group was 86%. | Source → |
| Bevacizumab Does Not Hinder Liver Regeneration | Colorectal Cancer | animal-study | — | Source → |
| Bevacizumab and Chemotherapy for Ovarian Cancer: A Systematic Review | Ovarian Cancer | meta-analysis | Bevacizumab combined with chemotherapy may improve progression-free survival and overall survival in patients with OC. | Source → |
| Olaparib and Bevacizumab Combination Extends Progression-Free Survival in Ovarian Cancer | Ovarian Cancer | phase-3 | Olaparib plus bevacizumab provided a substantial PFS benefit versus bevacizumab alone in the homologous recombination deficiency (HRD)-positive subgroup, with a 61% reduction of risk of progression or death in the higher-risk group and an 85% reduction in the lower-risk group. | Source → |
| Updated Guidelines for Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| New Cancer Treatment MIL60 Compared to Bevacizumab in Lung Cancer | Lung Cancer | phase-3 | The 12-week objective response rates (ORR12) in the MIL60 group and bevacizumab group were 48.6% and 43.1%, respectively. | Source → |
| Comparing a New Cancer Treatment to a Standard One | Lung Cancer | lab-study | — | Source → |
| New Research on Ovarian Cancer Treatment Options | Ovarian Cancer | review | — | Source → |
| Two Distinct Melanomas in the Same Eye Treated with Laser Therapy | Melanoma | observational | — | Source → |
| New Formulation of Cancer Drug Shows Promise for Lung Cancer Treatment | Lung Cancer | animal-study | The formulation was efficacious in an in vivo rat model for NSCLC at a 10-fold decrease in dose relative to the intravenous control. | Source → |
| Bevacizumab plus chemotherapy may be better for some colorectal cancer patients | Colorectal Cancer | observational | Patients treated with bevacizumab-based chemotherapy had a median overall survival of 30.0 months compared to 26.3 months for those treated with cetuximab-based chemotherapy. | Source → |
| Ovarian Cancer Treatment Study Finds Key Prognostic Factors | Ovarian Cancer | preclinical | Median progression-free survival was 20.8 months, and median overall survival was 41.1 months. | Source → |
| Ovarian Cancer Treatment Study Finds Different Effects on Mitochondria | Ovarian Cancer | lab-study | — | Source → |
| Combination Therapy Shows Promise for Late-Stage Colorectal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 5.6 months, and the median overall survival was 11.5 months. | Source → |
| CYFRA 21-1 May Help Predict Outcomes in Lung Cancer Patients | Lung Cancer | observational | Only normal values of CYFRA were associated with significantly better overall and progression-free survival. | Source → |
| New Chemotherapy Combination Shows Promise for Ovarian Clear Cell Carcinoma | Ovarian Cancer | phase-1 | Two evaluable patients showed a partial response. | Source → |
| Intraperitoneal Bevacizumab May Help Delay Malignant Ascites in Ovarian Cancer Patients | Ovarian Cancer | phase-2 | The proportion with a TTP of >42 days was 77% (95% CI 58-92). | Source → |
| Bevacizumab and chemotherapy improve survival in ovarian cancer patients | Ovarian Cancer | phase-3 | — | Source → |
| Bevacizumab's Effect on Recurrent Ovarian Cancer | Ovarian Cancer | observational | The median progression-free survival was 13 months in patients who received chemotherapy with bevacizumab, compared to 7 months in those who received chemotherapy only. | Source → |
| Combining Rucaparib and Bevacizumab in Ovarian Cancer Treatment | Ovarian Cancer | phase-1 | — | Source → |
| Bevacizumab Infusion Risks in Ovarian Cancer | Ovarian Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.